Parker Waichman LLP

Researcher’s Drug Industry Ties

  Drug Industry Payments Controversy. Late last year, we wrote about prominent Emory University professor Charles Nemeroff who lost his chairmanship following controversy over payments he received from drug companies.  In December, following an internal investigation, Nemeroff stepped down as head of the school’s Department of Psychiatry and Behavioral Sciences, a position he held since […]

Drug Industry

 

Drug Industry Payments Controversy. Late last year, we wrote about prominent Emory University professor Charles Nemeroff who lost his chairmanship following controversy over payments he received from drug companies.  In December, following an internal investigation, Nemeroff stepped down as head of the school’s Department of Psychiatry and Behavioral Sciences, a position he held since 1991.

Now, the Atlanta Journal-Constitution reports that federal officials are investigating both the university and Nemeroff and are looking into Nemeroff’s highly compensated activities with the pharmaceutical industry.

Although it is understood that industry hires scientists and physicians to test drug safety and efficacy for later use by the U.S. Food and Drug Administration (FDA) when drug approval is sought, strict procedures—including those surrounding financial information—are in place, but are clearly not always followed.

Nemeroff, said the Atlanta Journal-Constitution, a renowned, international expert on depression, has been mentioned a number of times in Grassely’s Congressional investigation.

Because of this growing problem, U.S. Republican Senator and ranking member of the Senate Finance Committee, Charles Grassley, urged the investigation and sent a letter this week to the inspector general of the U.S. Department of Health and Human Services (HHS), detailing his concerns and explaining that Nemeroff might be in violation of conflict-of-interest rules with regard to a number of grants Emory University received from the National Institutes of Health (NIH); Emory is required to report such conflicts to the NIH, Grassley said, according to the Atlanta Journal-Constitution.

Conflicts of interests can result in fines, fund freezes, and future grant loss

Conflicts of interests can result in fines, fund freezes, and future grant loss, said the Atlanta journal-Constitution, which noted that the NIH awarded Emory in excess of $251 million in 2008, about 61 percent of its total research grants.

To help ensure no conflict-of-interest opportunities present themselves, the government mandates all such conflicts be reported by clinical researchers responsible for reviewing medications in advance of drug companies applying for FDA approval.

But, earlier this year, the Inspector General’s Office said the FDA is not reliable when it comes to finding drug research conflicts of interest, a huge issue these days between medical professionals and industry.

In January, the Canadian Press reported that poor and late information and loopholes are to blame and that the FDA is integral to the problem, noting that the HHS said the FDA’s screening system is wanting and that it “found a number of limitations in FDA’s oversight, leaving FDA unable to determine whether (drug companies) submit financial information for all clinical investigators,” saying that such issues “could result in FDA being unaware of a clinical investigator’s financial interest, and thus unable to gauge its potential bias on clinical trial results.”

The report found that only 206 of the nearly 30,000 clinical investigators disclosed

As matter-of-fact, the report found that only 206 of the nearly 30,000 clinical investigators disclosed potential financial conflicts.

According to an earlier Wall Street Journal piece, Nemeroff failed to report to Emory over $800,000 he received from Glaxo for more than 250 speaking engagements from January 2000 to January 2006.

According to a prior Atlanta Journal-Constitution, Emory’s investigation also found that Nemeroff received income from other drug makers, but Glaxo was, by far, his biggest patron.

In October, we reported that documents released by Emory to Grassley’s investigators indicated that Nemeroff was paid more than $2 million by pharmaceutical companies, but failed to report over $1 million of that income to Emory while working on government-funded drug research.

The documents include a letter from Nemeroff dated July 15, 2004 in which he promises Emory administrators he would under $10,000 annually from GlaxoSmithKline in order to maintain federal compliance; however, Nemeroff actually earned $170,000 from Glaxo that very year.

Need Legal Help Regarding Drug Industry?

The personal injury attorneys at Parker Waichman LLP offer free, no-obligation case evaluations. For more information, fill out our online contact form or call 1-800-YOURLAWYER (1-800-968-7529).

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
Outstanding service!
Pamela Carter
5 years ago
5 Star Reviews 150
This law firm is excellent. The staff is always accessible, concerned, caring, and knowledgeable. My law team of Julie Trinidad, Maryann Galizzi, and Nurse Joanne are consistently working to assist and support me throughout this process. Thank you all.
Mike Primo
5 years ago
5 Star Reviews 150
Tina Morace provided me excellent support throughout the application process. She provided me with valuable follow-up on questions and any actions needed on my part. You have a valued employee with Tina
Joe Sinopoli
2 months ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038